Zentiva has officially entered the biosimilars market with the launch of its first monoclonal antibody, marking a significant strategic move for the company. This product aims to enhance access to high-quality biological medicines across Europe, fulfilling the company’s commitment to providing affordable healthcare solutions.
On December 1, 2025, Zentiva announced that its biosimilar has received approval from the European Medicines Agency (EMA), paving the way for its gradual rollout across EU markets. This development reinforces Zentiva’s position as a trusted partner in the pharmaceutical industry, focused on improving patient access to essential therapies.
Steffen Saltofte, Chief Executive Officer of Zentiva, described the launch as a pivotal moment for the company. “Today’s official introduction is a critical milestone for Zentiva,” he stated. “We have taken a significant step into the realm of biological medicines. Biosimilars are a natural continuation of our mission to deliver accessible and affordable quality medicines to patients across Europe. This expansion will also enable Zentiva to achieve sustainable growth in one of the most dynamic sectors of the pharmaceutical industry.”
Zentiva’s new biosimilar is designed for the treatment of bone diseases, contributing to a growing portfolio aimed at addressing the increasing demand for biologics in healthcare. The company’s entry into the biosimilars space is part of a broader strategic development plan that seeks to extend its offerings beyond traditional generic medicines.
As the share of biological medicines in healthcare spending continues to rise in Europe, biosimilars play a crucial role in ensuring the sustainability of healthcare systems and improving patient access to modern therapies. The introduction of Zentiva’s biosimilar is expected to enhance competition in the market, ultimately benefiting patients and healthcare providers alike.
With a commitment to health and comfort for all generations, Zentiva operates through the development, manufacturing, and supply of quality medicinal products for over 100 million patients in more than 30 countries across Europe and beyond. The company ensures the safety of its supply through four wholly owned manufacturing facilities and a broad network of external production partners.
Zentiva employs over 5,000 dedicated professionals who are committed to serving those who rely on its medicines every day. As a private company, Zentiva continues to pursue sustainable growth, looking ahead with ambitious plans for the future.
For more information, visit www.zentiva.com.
